Cellceutix to Pursue 505(b)(2) Clinical Process for Psoriasis Drug
Links shared publicly online about this topic.
- 0total visits
Cellceutix to Pursue 505(b)(2) Clinical Process for Psoriasis Drug
BEVERLY, MA--(Marketwire - Sep 26, 2011) - Cellceutix Corporation (OTCQB: CTIX) (PINKSHEETS: CTIX) (the "Company"), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat unmet medical conditions, today released pictures of its mice study with KM-133, the Company's small molecule acting on the principles of immune...
View full resource at marketwire.com
Tags: Immune, Psoriasis, Drug, Medical
Most Recently Shared on September 28, 2011 at 4:02 pm By:
Cellceutix: Cellceutix to Pursue 505(b)(2) Clinical Process for Psoriasis Drug: BEVERLY, MA (MARKET WIRE) Cellc... http://t.co/cRQ4zOYQ
Advertisement
